Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for Weight Loss in Obese Children
NCT00886626Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- May 2009
- Primary completion
- Feb 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of exenatide in obesity, sponsored by University of Minnesota. Primary endpoint: Change in Body Mass Index at 3 months. Started May 2009; status: completed.
02
Drugs
exenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00886626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00886626.